Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
Autor: | Veiga, Viviane C., Prats, João A. G. G., Farias, Danielle L. C., Rosa, Regis G., Dourado, Leticia K., Zampieri, Fernando G., Machado, Flávia R., Lopes, Renato D., Berwanger, Otavio, Azevedo, Luciano C. P., Avezum, Álvaro, Lisboa, Thiago C., Rojas, Salomón S. O., Coelho, Juliana C., Leite, Rodrigo T., Carvalho, Júlio C., Andrade, Luis E. C., Sandes, Alex F., Pintão, Maria C. T., Castro Jr, Claudio G. |
---|---|
Předmět: |
ARTIFICIAL respiration
BIOMARKERS C-reactive protein CONFIDENCE intervals FERRITIN LACTATE dehydrogenase OXYGEN therapy SERUM RANDOMIZED controlled trials TREATMENT effectiveness SEVERITY of illness index FIBRIN fibrinogen degradation products DESCRIPTIVE statistics ODDS ratio TOCILIZUMAB COVID-19 PHARMACODYNAMICS |
Zdroj: | BMJ: British Medical Journal; 2/13/2021, Vol. 372 Issue 8279, p1-9, 9p |
Databáze: | Complementary Index |
Externí odkaz: |